Selective glycoimmuno-targeting for cancer therapy

Projektinformationen

SweetAim

ID Finanzhilfevereinbarung: 716220

DOI

10.3030/716220

Projekt abgeschlossen

EK-Unterschriftsdatum 28 November 2016

Startdatum 1 Dezember 2016

Enddatum 30 November 2022

Finanziert unter

• EXCELLENT SCIENCE - European Research Council (ERC)

Gesamtkosten

€ 1 479 995,00

EU-Beitrag

€ 1 479 995,00

Koordiniert durch

TEL AVIV UNIVERSITY
Israel

Periodic Reporting for period 4 - SweetAim (Selective glycoimmuno-targeting for cancer therapy)

Berichtszeitraum: 2021-06-01 bis 2022-11-30

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

Cancer is a leading cause of death worldwide and new therapies are still needed. The primary objective of this proposal is to design a novel cancer therapeutic approach and to address the challenges faced by the study of carbohydrates immune recognition. It is based on findings that some tumor-associated carbohydrates can be targeted for cancer therapy. We investigated the potential of robust effective targeting of tumor-carbohydrates with antibodies both in vitro and in vivo. This research is has provided tools for designing novel therapeutics, imaging and diagnostics for cancer and for other chronic inflammation-related diseases, that are very important to reduce cancer burden for the benefit of society.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

We investigated carbohydrates as targets for antibody therapy in cancer. We explored the different factors that affect carbohydrate binding and recognition and developed several methods to improve antibody recognition and cancer killing potential both through passive therapy, as well as through active cancer vaccine design.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

We have already published fifteen papers and submitted 8 patents related to the use of antibodies for cancer diagnostics and therapy.

072120-nutri-red-meat-cancer-risk-low-resolution.jpg